Consecutive Hypoalbuminemia Predicts Inferior Outcome in Patients With Diffuse Large B-Cell Lymphoma

Wei, Xiaolei; Zheng, Jie; Zhang, Zewen; Liu, Qiongzhi; Zhan, Minglang; Huang, Weimin; Chen, Junjie; Wei, Qi; Wei, Yongqiang; Feng, Ru

doi:10.3389/fonc.2020.610681

Cited by 14 publications

(13 citation statements)

References 26 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we retrospectively confirmed that hypoalbuminemia was not uncommon at diagnosis of de novo ARL and was associated with poor survival outcome attractively. A similar trend was observed in the analyses of HIV-negative DLBCL patients [ 22 , 24 ]. We also uncovered a strong relationship between hypoalbuminemia and poor ECOG PS as well as higher IPI score.…”

Section: Discussionsupporting

confidence: 85%

“…These associations with adverse prognostic factors translated into shorter OS for ARL patients with hypoalbuminemia. This indicated that serum albumin level may be not only a surrogate of poor nutritional, but also driven by the aggressive tumor behavior and inflammatory status [ 24 , 28 ], which was correlated with shorter survival, treatment response, treatment-related toxicity and compliance [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hypoalbuminemia predicts inferior outcome in patients with AIDS-related lymphoma

Zhang

Xie

Cai

et al. 2022

Infect Agents Cancer

View full text Add to dashboard Cite

Background The prognostic value of serum albumin in acquired immunodeficiency syndrome (AIDS)-related lymphoma (ARL) remains covered. Methods We retrospectively analyzed de novo ARL patients from 2013 to 2019 across three centers. Factors correlated with progression-free survival (PFS) and overall survival (OS) were evaluated in Kaplan–Meier, univariate and multivariate Cox proportional hazard models. Results A total of 86 ARL patients were enrolled with a median follow-up of 34 months. In the cohort, the OS and 2-year PFS rates were 37.5% and 35.4%, respectively. In multivariate models, older age (PFS, hazard ratios [HR] = 1.035, p = 0.037; OS, HR = 1.034, p = 0.041) and hypoalbuminemia (OS, HR = 0.910, p = 0.038) predicted inferior survival. ARL patients with hypoalbuminemia showed worse OS and 2-year PFS (p = 0.028 and p = 0.01, respectively), which was associated with poor Eastern Cooperative Oncology Group performance status (ECOG PS) and higher International Prognosis Index (IPI) score. Conclusion In conclusion, serum albumin at diagnosis is an independent prognostic factor for overall survival in AIDS-related lymphoma.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Hypoalbuminemia predicts inferior outcome in patients with AIDS-related lymphoma

Zhang

Xie

Cai

et al. 2022

Infect Agents Cancer

View full text Add to dashboard Cite

show abstract

“… 13 , 24 , 25 , 26 , 27 Hypoalbuminaemia is a predictive factor for shorter survival, decreased relative dose intensity of anthracycline and cyclophosphamide, and increased risk of TRM. 28 , 29 , 30 , 31 , 32 High NLR is also correlated with shorter survival, lower CR rate, advanced stage, higher LDH level, and increased risk of depression. 32 , 33 , 34 , 35 , 36 , 37 The CXI comprehensively assesses these clinical parameters, and therefore may more effectively overcome the bias caused by confounding factors affecting the clinical outcomes of the patients than any single parameter of cancer cachexia.…”

Section: Discussionmentioning

confidence: 98%

Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B‐cell lymphoma

Park

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Cancer cachexia is known to adversely affect the clinical course in patients with malignant lymphoma. The cachexia index (CXI) is a potential biomarker of cancer cachexia, and its implications for the prognosis and treatment outcome of lung cancer and aggressive lymphoma has been assessed in previous studies. Methods A total of 267 patients diagnosed with diffuse large B‐cell lymphoma who were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) immunochemotherapy were retrospectively reviewed. The CXI was calculated as the skeletal muscle index (SMI) × serum albumin/neutrophil–lymphocyte ratio (NLR). Although previous studies measured the SMI using the muscles of the L3 vertebral level, the present study used both the L3 vertebral muscles and the pectoralis muscles (PM) at the T4 vertebral level to measure the SMI. Depending on the type of muscles used, the CXI was termed the L3‐CXI or PM‐CXI. Using sex‐specific cutoff values for CXI, the patients were categorized as follows: (i) high‐CXI group (high L3‐CXI and high PM‐CXI), (ii) intermediate‐CXI group (high L3‐CXI and low PM‐CXI), and (iii) low‐CXI group (low L3‐CXI and low PM‐CXI). Results Complete responses to R‐CHOP were obtained in 145/173 (83.8%), 25/36 (69.4%), and 27/57 (47.4%) patients in the high‐CXI, intermediate‐CXI, and low‐CXI groups, respectively (P < 0.001). Treatment‐related anaemia (15.6%, 30.6%, and 26.3%, P = 0.038), thrombocytopenia (21.4%, 36.1%, and 43.9%, P < 0.001), febrile neutropenia (23.7%, 44.4%, and 36.8%, P = 0.022), and any nonhaematologic toxicity (31.2%, 44.4%, and 54.4%, P = 0.001) of Grade 3 or more were more common in the lower CXI groups than in the higher‐CXI groups. Early treatment discontinuation for reasons other than lymphoma progression also occurred more frequently in the low‐CXI group (24/57, 42.1%) compared with the intermediate‐CXI (5/36, 13.9%) and high‐CXI (18/173, 10.4%) groups (P < 0.001). Median overall survival in the high‐CXI, intermediate‐CXI, and low‐CXI groups was not reached, 50.6 months, and 14.5 months, respectively (p < 0.001). Multivariable analysis showed that low CXI was an independent negative prognostic factor for overall survival (hazard ratio 2.103, 95% confidence interval 1.278–3.460, P = 0.003). Conclusions We suggest that in patients with diffuse large B‐cell lymphoma, the CXI is a biomarker for cancer cachexia that can predict survival, treatment response, treatment‐related toxicity, and compliance with R‐CHOP. Patients were more clearly stratified by this new CXI category compared with the classifications described in previous studies.

show abstract

“… 15 Based on the function of ALB, T‐CHOL, and TL, the associations between CONUT score and the basic variables of ENKTL might be clarified, as ALB, for an example, is used for the assessment of nutritional status as well as immune function. 28 Most cancer patients diagnosed with hypoalbuminemia were placed in the advanced stage category. When the ALB level is less than 30 g/L, the body might not be able to resist the invasion of foreign pathogens, resulting in the release of inflammatory cytokines, which might cause B symptoms.…”

Section: Discussionmentioning

confidence: 99%

A controlling nutritional status score is an independent predictor for patients with newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma based on asparaginase‐containing regimens

Ren

Chen

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Background The controlling nutritional status (CONUT) score is a nutritional index that combines serum albumin, total cholesterol, and lymphocyte counts. The potential value of CONUT score for predicting clinical outcomes in patients with nasal‐type extranodal NK/T‐cell lymphoma (ENKTL) has not been explored. Methods This study included 374 ENKTL patients treated with asparaginase‐containing regimens from September 2012 to September 2017. Clinical characteristics, treatment efficacy, prognostic factors, and the predictive value of CONUT score were analyzed. Results The complete response (CR) and overall response rate (ORR) were 54.8% and 74.6%, respectively. Patients with CONUT scores <2 had higher CR and ORR compared to patients with scores ≥2 (69.1% vs. 48.9% for CR, p = 0.001; 90.0% vs. 74.6% for ORR, p < 0.001). The 5‐year overall survival (OS) and progression‐free survival (PFS) rates were 61.9% and 57.3%, respectively. Patients with CONUT scores <2 had better survival outcomes than those with scores ≥2 (5‐year OS, 76.1% vs. 56.0%, p < 0.001; 5‐year PFS, 74.4% vs. 50.1%, p < 0.001). CONUT score ≥2 was identified as an independent poor prognostic factor for both OS and PFS. A CONUT score ≥2 was also associated with poorer survival outcomes in low‐risk ENKTL patients. Conclusion A CONUT score ≥2 is a prognostic marker for poor survival in patients with ENKTL and could be used to stratify risk in low‐risk patients.

show abstract

Consecutive Hypoalbuminemia Predicts Inferior Outcome in Patients With Diffuse Large B-Cell Lymphoma

Cited by 14 publications

References 26 publications

Hypoalbuminemia predicts inferior outcome in patients with AIDS-related lymphoma

Hypoalbuminemia predicts inferior outcome in patients with AIDS-related lymphoma

Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B‐cell lymphoma

A controlling nutritional status score is an independent predictor for patients with newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma based on asparaginase‐containing regimens

Contact Info

Product

Resources

About